Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

A Prospective Randomized Comparison of HDAC vs AD in the Induction Chemothrapy for AML.

Phase 3

Conditions: Acute Myeloid Leukemia

Interventions: Drug: High dose Cytarabine
Drug: Cytarabine
Drug: Hign dose Daunorubicin

First Posted Date: 2018-04-25

Last Posted Date: 2020-01-13

Lead Sponsor: Asan Medical Center

Target Recruit Count: 380

Registration Number: NCT03507842

Locations: 🇰🇷
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of

Epacadostat, Cladribine and Cytarabine (ECC) in AML

Phase 1

Withdrawn

Conditions: Relapse
AML

Interventions: Drug: Epacadostat
Drug: Cladribine
Drug: Cytarabine

First Posted Date: 2018-04-09

Last Posted Date: 2018-09-11

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Registration Number: NCT03491579

Locations: 🇨🇭
Departement of Medical Oncology, University Hospital Berne, Berne, Switzerland

Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

Phase 2

Terminated

Conditions: Acute Lymphoblastic Leukemia in Remission
B Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Biological: Inotuzumab Ozogamicin
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Drug: Mercaptopurine
Drug: Methotrexate
Biological: Ofatumumab
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2018-04-04

Last Posted Date: 2024-07-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT03488225

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL

Phase 1

Active, not recruiting

Conditions: Acute Lymphocytic Leukemia, Pediatric
B-cell Acute Lymphoblastic Leukemia

Interventions: Biological: Chimeric Antigen Receptor T-Cell Therapy
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Tocilizumab
Drug: Cytarabine
Drug: Etoposide
Drug: Dexamethasone

First Posted Date: 2018-03-15

Last Posted Date: 2023-02-24

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 18

Registration Number: NCT03467256

Locations: 🇷🇺
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS

Phase 1

Completed

Conditions: AML
Advanced Myelodysplastic Syndromes
MDS
Acute Myelogenous Leukemia

Interventions: Drug: Pevonedistat
Drug: Cytarabine

First Posted Date: 2018-03-09

Last Posted Date: 2021-12-28

Lead Sponsor: Justin Watts, MD

Target Recruit Count: 12

Registration Number: NCT03459859

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

Epacadostat, Idarubicin and Cytarabine (EIC) in AML

Phase 1

Withdrawn

Conditions: AML

Interventions: Drug: Epacadostat
Drug: Idarubicin
Drug: Cytarabine
Drug: Daunorubicin

First Posted Date: 2018-02-23

Last Posted Date: 2018-09-11

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Registration Number: NCT03444649

Locations: 🇨🇭
Departement of Medical Oncology, University Hospital Berne, Berne, Switzerland

Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Biological: Lintuzumab-Ac-225
Drug: Cladribine
Drug: Cytarabine
Drug: Mitoxantrone
Drug: G-CSF

First Posted Date: 2018-02-22

Last Posted Date: 2024-10-07

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 26

Registration Number: NCT03441048

Locations: 🇺🇸
Froedtert Hospital and the Medical College of Wisconsin, Milwuakee, Wisconsin, United States

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Phase 2

Recruiting

Conditions: Clonal Cytopenia of Undetermined Significance
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Hodgkin Lymphoma
Recurrent Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Lymphoma
Chronic Myelomonocytic Leukemia

Interventions: Dietary Supplement: Ascorbic Acid
Drug: Carboplatin
Drug: Decitabine
Drug: Cisplatin
Drug: Cytarabine
Drug: Dexamethasone
Drug: Etoposide
Drug: Gemcitabine Hydrochloride
Procedure: Central Venous Cannula Insertion
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis
Other: Placebo Administration
Procedure: Portacath Placement
Other: Questionnaire Administration
Biological: Rituximab
Drug: Oxaliplatin
Procedure: Biospecimen Collection
Procedure: Core Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Echocardiography
Procedure: Positron Emission Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Computed Tomography

First Posted Date: 2018-02-01

Last Posted Date: 2024-08-05

Lead Sponsor: Mayo Clinic

Target Recruit Count: 80

Registration Number: NCT03418038

Locations: 🇺🇸
Mayo Clinic Health System-Eau Claire Clinic, Eau Claire, Wisconsin, United States
🇺🇸
Mayo Clinic Health Systems-Mankato, Mankato, Minnesota, United States
🇺🇸
Mayo Clinic Health System-Franciscan Healthcare, La Crosse, Wisconsin, United States

and more 1 locations

A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: azacitidine
Drug: glasdegib
Drug: daunorubicin + cytarabine
Drug: Placebo
Drug: cytarabine
Procedure: HSCT

First Posted Date: 2018-01-31

Last Posted Date: 2023-04-21

Lead Sponsor: Pfizer

Target Recruit Count: 730

Registration Number: NCT03416179

Locations: 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇵🇱
WWCOiT im. M. Kopernika w Lodzi, Lodz, Poland

and more 146 locations

A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML

Phase 2

Recruiting

Conditions: Leukemia, Myeloid

Interventions: Drug: Decitabine and Ara-C
Drug: Ara-C

First Posted Date: 2018-01-31

Last Posted Date: 2020-04-27

Lead Sponsor: Xuejie Jiang

Target Recruit Count: 100

Registration Number: NCT03417427

Locations: 🇨🇳
Nanfang Hospital of Southern Medical University, Guanzhou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy